The Exchange has sought clarification from Aurobindo Pharma Limited with respect to recent news item captioned "FDA Woes Hit Aurobindo Pharma As Unit 4 Gets Nine Observations". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Aurobindo Pharma Limited has submitted their response.